-
Loading metrics
Open Access
Peer-reviewed
Research Article
CYP51 is an essential drug target for the treatment of primary amoebic meningoencephalitis (PAM)
-
Anjan Debnath,
Roles Investigation, Methodology, Resources, Writing – review & editing
Affiliation Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, United States of America
⨯ -
Claudia M. Calvet,
Roles Investigation, Methodology, Visualization, Writing – review & editing
Affiliations Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, United States of America, Cellular Ultrastructure Laboratory, Oswaldo Cruz Institute, FIOCRUZ, Rio de Janeiro, RJ, Brazil
⨯ -
Gareth Jennings,
Roles Investigation, Methodology, Writing – review & editing
Affiliation Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, United States of America
⨯ -
Wenxu Zhou,
Roles Investigation, Methodology, Writing – review & editing
Affiliation Department of Chemistry & Biochemistry, Texas Tech University, Lubbock, Texas, United States of America
⨯ -
Alexander Aksenov,
Roles Investigation, Methodology, Writing – review & editing
Affiliation Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, United States of America
⨯ -
Madeline R. Luth,
Roles Investigation
Affiliation Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, United States of America
⨯ -
Ruben Abagyan,
Roles Methodology, Software
Affiliation Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, United States of America
⨯ -
W. David Nes,
Roles Data curation, Methodology, Resources, Supervision
Affiliation Department of Chemistry & Biochemistry, Texas Tech University, Lubbock, Texas, United States of America
⨯ -
James H. McKerrow,
Roles Funding acquisition, Methodology, Resources, Writing – review & editing
Affiliation Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, United States of America
⨯ -
Larissa M. Podust
Roles Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Writing – original draft, Writing – review & editing
* E-mail: lpodust@ucsd.edu
Affiliation Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, United States of America
⨯
CYP51 is an essential drug target for the treatment of primary amoebic meningoencephalitis (PAM)
- Anjan Debnath,
- Claudia M. Calvet,
- Gareth Jennings,
- Wenxu Zhou,
- Alexander Aksenov,
- Madeline R. Luth,
- Ruben Abagyan,
- W. David Nes,
- James H. McKerrow,
- Larissa M. Podust
- Published: December 28, 2017
- https://doi.org/10.1371/journal.pntd.0006104